Product Description
LZM-009 is being developed by Livzon Group for the treatment of patients with Relapsed or Refractory T-Cell Lymphoma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04712864?term=LB-1901&draw=2&rank=1)
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Livzon Group
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20200784 | P2 |
Active, not recruiting |
Oncology Unspecified |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/16/2021 |
News Article |
Bright Peak Therapeutics Licenses Rights to Livzon's Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines |